• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Treatment of lipid disorders].

作者信息

Custodis F, Laufs U

机构信息

Klinik f. Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinik des Saarlandes, 66421, Homburg/Saar, Deutschland,

出版信息

Herz. 2014 Feb;39(1):119-28; quiz 129-30. doi: 10.1007/s00059-013-4013-x.

DOI:10.1007/s00059-013-4013-x
PMID:24469010
Abstract

Lipid disorders play an essential role in the pathogenesis of atherosclerotic diseases. An integral part of the clinical evaluation is the estimation of the individual cardiovascular risk using risk scores and patient history. Due to the long established prognostic relevance, reduction of low-density lipoproteins (LDL) using statins remains beyond doubt the central intervention both in primary and secondary prevention of atherosclerotic diseases. Indispensible components of treatment in all patients with elevated triglyceride levels are lifestyle changes contributing to a reduction of accompanying risk factors, in particular physical activity and smoking cessation.

摘要

相似文献

1
[Treatment of lipid disorders].
Herz. 2014 Feb;39(1):119-28; quiz 129-30. doi: 10.1007/s00059-013-4013-x.
2
Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.HMG-CoA还原酶抑制剂与贝特类衍生物联合治疗:对潜在益处与弊端的批判性综述
Am J Cardiovasc Drugs. 2003;3(3):169-78. doi: 10.2165/00129784-200303030-00003.
3
Effect of fluvastatin in combination with moderate endurance training on parameters of lipid metabolism.氟伐他汀联合适度耐力训练对脂质代谢参数的影响。
Sports Med. 1999 May;27(5):329-35. doi: 10.2165/00007256-199927050-00004.
4
Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.苯扎贝特。其药理学及在血脂异常管理中的应用的最新进展。
Drugs. 1996 Nov;52(5):725-53. doi: 10.2165/00003495-199652050-00008.
5
Beyond statins: what to expect from add-on lipid regulating therapy?除了他汀类药物:附加脂质调节疗法的预期效果如何?
Eur Heart J. 2013 Sep;34(34):2660-5. doi: 10.1093/eurheartj/eht213. Epub 2013 Jul 4.
6
2017 Taiwan lipid guidelines for high risk patients.2017年台湾高危患者血脂指南。
J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24.
7
Shifting views on lipid lowering therapy.对降脂治疗的观点转变。
BMJ. 2010 Jul 28;341:c3531. doi: 10.1136/bmj.c3531.
8
[Goals and practical implementation of lipid therapy in coronary heart disease].
Herz. 1997 Jun;22(3):134-40. doi: 10.1007/BF03044350.
9
[Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].[心血管并发症的残余风险及其通过联合降脂药物降低的情况]
Vnitr Lek. 2011 Mar;57(3):313-6.
10
Efficacy of low-density-lipoprotein lowering with statins.
Lancet. 1994 Sep 3;344(8923):683.

本文引用的文献

1
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.针对枯草溶菌素转化酶 9 治疗血脂异常和动脉粥样硬化。
J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21.
2
Pharmacotherapies for lipid modification: beyond the statins.调脂药物治疗:超越他汀类药物。
Nat Rev Cardiol. 2013 Oct;10(10):560-70. doi: 10.1038/nrcardio.2013.117. Epub 2013 Aug 20.
3
Beyond statins: what to expect from add-on lipid regulating therapy?除了他汀类药物:附加脂质调节疗法的预期效果如何?
Eur Heart J. 2013 Sep;34(34):2660-5. doi: 10.1093/eurheartj/eht213. Epub 2013 Jul 4.
4
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.血脂异常的新治疗原则:重点关注 LDL 和 Lp(a)降低药物。
Eur Heart J. 2013 Jun;34(24):1783-9. doi: 10.1093/eurheartj/eht088. Epub 2013 Mar 18.
5
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.HPS2-THRIVE 随机安慰剂对照试验纳入 25673 例 ER 烟酸/拉罗匹仑的高危患者:试验设计、预先指定的肌肉和肝脏结局以及停止研究治疗的原因。
Eur Heart J. 2013 May;34(17):1279-91. doi: 10.1093/eurheartj/eht055. Epub 2013 Feb 26.
6
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.他汀类药物降低 LDL 胆固醇对低血管疾病风险人群的影响:27 项随机试验个体数据的荟萃分析。
Lancet. 2012 Aug 11;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5. Epub 2012 May 17.
7
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.烟酸在接受强化他汀类药物治疗的低 HDL 胆固醇水平患者中的应用。
N Engl J Med. 2011 Dec 15;365(24):2255-67. doi: 10.1056/NEJMoa1107579. Epub 2011 Nov 15.
8
[Hypertricglyceridemia: prognostic impact and treatment options].[高甘油三酯血症:预后影响及治疗选择]
Dtsch Med Wochenschr. 2011 Jul;136(30):1533-42. doi: 10.1055/s-0031-1281550. Epub 2011 Jul 25.
9
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).ESC/EAS 血脂异常管理指南:欧洲心脏病学会(ESC)和欧洲动脉粥样硬化学会(EAS)血脂异常管理工作组
Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093/eurheartj/ehr158. Epub 2011 Jun 28.
10
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.更强化降低 LDL 胆固醇的疗效和安全性:来自 26 项随机试验中 170000 名参与者数据的荟萃分析。
Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.